pepdex
← Back to index
№ 061

Pramlintide (Symlin)

Synthetic analog of amylin (the satiety hormone co-secreted with insulin). FDA-approved 2005 as mealtime adjunct in type 1 and type 2 diabetes. The clinical predecessor to Cagrilintide.

Fat Loss
Evidence: Strong
Half-life
~50 minutes
Route
Subcutaneous, before meals
Cycle
Long-term in diabetes management
Schedule
Pre-meal injection (multiple times daily)
In plain English

Pramlintide (sold as Symlin) is the synthetic copy of amylin — a satiety hormone your pancreas releases alongside insulin. FDA-approved as a mealtime injection for diabetes. It's the predecessor to Cagrilintide, just shorter-acting and used differently.

Status & legality
Natty?
Not natty
FDA
Approved

Approved as Symlin (2005) as adjunct to mealtime insulin in T1D and T2D.

Compounding
Approved drug

Available as an FDA-approved drug, not a compounded peptide.

WADA
Not listed
Prescribed

Yes — endocrinology providers prescribe in insulin-using diabetes contexts.

Who it's for

  • →T1D or T2D patients struggling with post-meal glucose spikes
  • →Mealtime-insulin users wanting better satiety
  • →Educational reference for amylin pathway

What to expect

  1. Week 1

    Post-meal glucose excursions reduce. Satiety improves.

  2. Week 4

    Insulin requirements often drop 30-50%.

  3. Week 8

    Stable adjunct effect.

How it works (mechanism)

Synthetic amylin analog with three proline substitutions to prevent the aggregation that limits native amylin's drug suitability. Slows gastric emptying and reduces post-meal glucagon.

Dosing protocol

T1D: start 15 mcg pre-meal, titrate to 30-60 mcg. T2D: start 60 mcg, titrate to 120 mcg.

Stacks well with

Mealtime insulin (mandatory for T1D context)

Side effects

01Severe hypoglycemia (when paired with insulin without dose adjustment — boxed warning)
02Nausea, vomiting
03Anorexia
04Headache

When NOT to use

  • ⚠Hypoglycemia unawareness
  • ⚠Gastroparesis
  • ⚠A1C > 9%
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • A1C
  • • Glucose monitoring
  • • Fasting insulin if on insulin therapy

Common mistakes

  • • Not reducing mealtime insulin by 50% on first dose (causes severe hypoglycemia)
  • • Using it for non-diabetic weight loss (off-label, less effective than Cagrilintide)
  • • Skipping the pre-meal timing

Drug & supplement interactions

  • ⚠MUST reduce mealtime insulin by 50% on first dose to prevent severe hypoglycemia (boxed warning)
  • ⚠Drugs that delay gastric emptying (anticholinergics) compound the slowing effect
  • ⚠Oral medications requiring rapid absorption: dose 1 hour before pramlintide

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Pramlintide (Symlin)?+
Pramlintide (sold as Symlin) is the synthetic copy of amylin — a satiety hormone your pancreas releases alongside insulin. FDA-approved as a mealtime injection for diabetes. It's the predecessor to Cagrilintide, just shorter-acting and used differently.
Is Pramlintide (Symlin) FDA approved?+
Approved as Symlin (2005) as adjunct to mealtime insulin in T1D and T2D.
Is Pramlintide (Symlin) banned by WADA?+
Pramlintide (Symlin) is not currently on the WADA prohibited list.
Are you still natty after taking Pramlintide (Symlin)?+
No. Pramlintide (Symlin) is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Pramlintide (Symlin)?+
Yes — endocrinology providers prescribe in insulin-using diabetes contexts.
What's the typical dose of Pramlintide (Symlin)?+
T1D: start 15 mcg pre-meal, titrate to 30-60 mcg. T2D: start 60 mcg, titrate to 120 mcg.
What are the side effects of Pramlintide (Symlin)?+
Common side effects include: Severe hypoglycemia (when paired with insulin without dose adjustment — boxed warning); Nausea, vomiting; Anorexia; Headache. Less common effects and full safety details are on the entry page.
How long until Pramlintide (Symlin) starts working?+
Post-meal glucose excursions reduce. Satiety improves.

More in Fat Loss

№ 008
Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

№ 009
Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.